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A B S T R A C T
HPV infections are common and the presence of the same high-risk type in cervical specimens can be due to reinfection
or persistence. Persistent infection is the most important predictor for development of cervical carcinoma. The aim of this
study was to validate PCR-RFLP with two sets of primers: MY09/MY11 that amplify a fragment of L1 and P1/P2 that
amplify a fragment of E1 ORF. PCR product of MY09/MY11 was digested with a set of 6 restriction enzimes (RE) and
PCR product of P1/P2 with a set of 12 RE. Cervical samples from 110 women patients of the University Gynecologic
Clinic CHC Zagreb were analyzed. There were 98 (89.1%) PCR positive samples detected with P1/P2 primers, and 94
(85.5%) PCR positive samples detected with MY09/MY11 primers. Seven HPV types were detected with P1/P2-RFLP
technique and 17 with MY09/MY11-RFLP. PCR positive samples amplified with both primer pairs agreed with each
other in 82 samples; 16 samples were only positive with P1/P2 and 12 samples were only positive by MY09/MY11. HPV
16 was detected in 39 samples with MY09/11-RFLP, out of these two variants (two different patterns) were found with
P1/P2 using Dde I, Hae III and Eco I. HPV 6 was detected in 9 samples with MY09/11-RFLP, out of these two variants
were found with P1/P2 using HinfI. Combining these two PCR-RFLP methods subtypes of HPV 16 and HPV 6 were de-
tected.
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Introduction
Human papillomaviruses (HPV) are small DNA vi-
ruses that cause proliferation of cutaneous and mucosal
epithelia. Over 150 types of HPV are known to date,
among these about 40 genotypes infect anogenital re-
gion. HPVs can be grouped into low- and high- risk types
and some authors also differentiate a third, probably
high-risk group1.
It has been proved that the subsequent development
of virtually all cervical cancers requires infection of the
uterine cervix with one of high-risk types of HPV1–4.
However, HPV infections are extremely common in
sexually active women and most are transient and be-
nign4–8.
Unfortunately, some HPV infected women do not
spontaneously clear their infections and instead develop
persistence. Persistence is defined as the presence of a
particular HPV high-risk genotype in two independent
cervical specimens obtained 6 month apart. Persistent
infection is the most important predictor for the develop-
ment of cervical carcinoma. The presence of the same
high-risk genotype in cervical specimens may be due to
reinfection so subtyping (the determination of the HPV
subtype) could help in a closer examination of persis-
tence.
Various consensus primer pairs have been used for a
polymerase chain reaction (PCR) based method of HPV
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detection. Most commonly used is the MY09/MY11 pri-
mer set9. Some authors found that the use of multiple
sets of PCR primers allow the detection of DNA of HPVs
in a higher proportion of cervical neoplasias compared
with the use of a single set of PCR primers. It was also
shown that PCR for HPV detection using a single set of
PCR primers, even the most sensitive one, is not ade-
quate for detecting a broad spectrum of HPV DNA types10.
The aim of this study was to validate a combined tech-
nique of PCR-restriction fragment length polymorphism
(RFLP). The first pair of primers used was MY09/MY11.
This set of primers is the one validated most often for de-
tecting and genotyping of broad spectrum of genital HPV
types. The second pair of primers used was P1/P2. This
set of consensus primers is able to promote the amplifica-
tion of a 526–594 bp fragment of E1 ORF, which contain
sequences from different mucosotropic HPV types11.
Combining these methods a higher sensitivity may be
expected, to resolve mixed infections and possibly to find
subtypes. The HPV subtypes detecting is very important
as a persistence proof.
Materials and Methods
Patients
110 HPV positive cervical samples were taken from
women patients of the Gynecologic clinic. Brush swabs
were used to obtain the endocervical samples, which
were taken during routine gynecologic examination.
Samples were taken from women patients of the Univer-
sity Gynecologic clinic CHC Zagreb in the period between
1 September 2003 and 1 October 2005. They were di-
vided in to 2 groups: one group consisted of 40 women
with cervical intraepithelial neoplasia (CIN) 1, another
of 40 women with CIN 2 or CIN 3. The control group con-
sisted of 30 women with negative cytology. The samples
were HPV positive by at least one of the two different
general primer PCR-based methods (MY09/MY11 and
P1/P2).
Cervical samples were collected in the commercial
transport medium HC 2 (Digene Specimen Collection
Kit, Silver Spring, Maryland, USA) and were stored at
–20 °C until procedure.
All the patients gave informed written consent and
the institutional review board approved the study.
Methods
DNA extraction. Total DNA was extracted from com-
mercial transport medium HC 2. Proteinase K (800 µL/
mL) and 2 µL of Tween-20 were added to the sterile mi-
cro tube with 200 µL of samples. This mixture was placed
in a thermo block at 55 °C for at least 2 hours. Proteinase
K was afterwards inactivated at 95 °C for 10 minutes.
DNA concentration and quality were determined by 1%
gel electrophoresis.
HPV detection by PCR. The isolated DNAs were
tested for the presence of HPV DNA by using general
primers PCR-based method. Degenerated consensus
primer pair MY09/MY11 amplifies an approximately 450
bp fragment in the L1 ORF. The other primer pair
(P1/P2) amplifies a 526–595 bp fragment in the E1 ORF.
HPV DNAs in specimens were amplified using PCR
primer pairs MY09/MY11 and P1/P2 as previously des-
cribed9,11. A 260-bp fragment of the cellular b-globin gene
was also amplified as previously described12. Successful
amplification of the b-globin gene fragment indicated
that the DNA sample was adequate for HPV DNA geno-
typing analysis and that no PCR inhibitors were present.
The specimens with negative b-globin amplification were
not taken into consideration.
HPV genotyping. To determine HPV type, PCR prod-
ucts of amplification with MY09/MY11 were digested
with restriction enzymes and afterwards were analyzed
by agarose gel electrophoresis, as previously described9.
PCR products of amplification with P1/P2 primer pair
were digested with 12 restriction endonucleases (RE)
(BamH I, Dde I, Hae II, Hinf I, Pst I, Rsa I, Alu I, Nsi I,
Hpa II, Bgl II, Ecor I, Kpn I) and were afterwards also
analyzed by agarose gel electrophoresis. The PCR prod-
uct of MY09/MY11 was digested with 6 RE and the PCR
product of P1/P2 was digested with 12 RE.
Results
The study comprised cervical samples taken from 110
women which were HPV positive by at least one of two
different general primer PCR-based methods: MY09/
MY11 and P1/P2. There were 98 positive samples with
the set of general primers P1/P2; the sensitivity of the
method was 89.1%. There were 94 (85.5%) PCR positive
samples with the primer set MY09/MY11. PCR positive
samples amplified by both primer pairs agreed with each
other in 82 cases. Sixteen (16) samples were only positive
by P1/P2 and 12 samples were only positive by MY09/
MY11 (Table 1).
Out of the 30 control samples (women with normal
cytology), in 5 samples (16.7%) the quantity of DNA was
too low for genotyping by the RFLP method. Therefore, a
total of 105 cervical samples were genotyped and 17 dif-
ferent genotypes were found (Table 2).
The most common genotypes were HPV 16 (37.1%),
HPV 31 (8.6%) and HPV 6 (8.6 %). Six samples remained
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TABLE 1
PCR PRIMERS USED AND NUMBER OF WOMEN WITH
DIFFERENT CYTOLOGICAL RESULTS
Primer pair
No. of women with different
cytological results
MY09 /
MY11
P1 / P2
Normal
CIN 1
CIN 2 and / or 3
Rates of de-
tection (%)
+ + 17 33 32 82 (74.6%)
– + 7 4 5 16 (14.5%)
+ – 6 3 3 12 (10.9%)
Total 30 40 40 110 (100 %)
untyped (HPV X – 5.7 %) and in 8 samples (7.6 %) mixed
infections were found (Table 2).
Amplified sequences were analyzed by restriction
fragment length polymorphism (RFLP). Seventeen dif-
ferent types were found with MY09/11-RFLP. Seven dif-
ferent patterns (types) were found with RFLP method
performed on E1 ORF.
HPV 16 was detected in 39 samples with MY09/
11-RFLP (standard method).
Out of the 39 samples determined as HPV16 by the
standard method, the use of P1/P2 primers gave 2 differ-
ent patterns after restriction. The HPV16a pattern was
found in 16 samples and the HPV16b pattern in 23 sam-
ples. The restriction method was carried out with 12 en-
zymes after P1/P2 amplification, but the following en-
zymes were sufficient to prove these subtypes: AluI,
HaeIII, EcoRI and Dde. Using restriction with AluI gave
one fragment in HPV16a, and digested HPV16b into 2
fragments. HaeIII, EcoRI and Dde digested HPV16a, but
there was no restriction in HPV16b.
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TABLE 2
DISTRIBUTION OF HPV TYPES IN WOMEN WITH DIFFERENT
CYTOLOGICAL RESULTS
Type
No of women with different
cytological results
Total N %
Normal CIN 1
CIN 2 or /
and CIN 3
6 6 3 9 8.6
11 3 3 2.9
16 5
10
p=1.0000
24
p=0.0198
39 37.1
18 2 2 4 3.8
31 2 3 4 9 8.6
33 1 2 3 2.9
39 1 1 0.9
40 2 3 5 4.8
52 2 2 1.9
53 1 3 1 5 4.8
56 2 2 1.9
58 1 3 4 3.8
61 1 1 0.9
62 1 2 3 2.9
73 1 1 0.9
X 2 3 1 6 5.7
16 + 70 1 1 0.9
33 + X 1 2 3 2.9
54 + X 2 2 1.9
58 + X 2 2 1.9
Total 25 40 40 105 100.0
TABLE 3
VARIANTS (SUBTYPES) OF HPV 6 AND HPV 16 COMPARING
WITH DIFFERENT GROUPS OF WOMEN
Subtypes*
No of women with different
cytological results Total
Normal CIN 1 CIN 2 3
HPV 16-a 2 7 7 16
HPV 16-b 3 3 17 23
HPV 6 -a 2 2 0 4
HPV 6-b 4 1 0 5
*PCR-RFLP after amplification with p1/p2
Fig. 1. RFLP patterns of PCR products amplified with primer
pair p1/p2 HPV 16 (variant 1). Agarose gel electrophoresis of
PCR products digested with different restriction enzymes. Lane
M: 100-bp ladder. Lane 1: BamH I (undigested), lane 2: Dde I
(digested), lane 3: Hae III (digested), lane 4: Hinf I (undigested),
lane 5: Pst I (undigested), lane 6: Rsa I (digested), lane 7: Alu I
(digested), lane 8: Nsi I (undigested), lane 9: Bgl I (undigested),
lane 10: Hpa II (undigested), lane 11: EcoR I (digested), lane 12:
Kpn I (undigested).
Fig. 2. RFLP patterns of PCR products amplified with primer
pair p1/p2 HPV 6 (variant 2). Agarose gel electrophoresis of PCR
products digested with different restriction enzymes. Lane M:
100-bp ladder. Lane 1: BamH I (undigested), lane 2: Dde I (undi-
gested), lane 3: Hae III (digested), lane 4: Hinf I (digested), lane
5: Pst I (undigested), lane 6: Rsa I (digested), lane 7: Alu I (undi-
gested), lane 8: Nsi I (digested), lane 9: Bgl I (undigested), lane
10: Hpa II (undigested), lane 11: EcoR I (undigested), lane 12:
Kpn I (digested).
HPV 6 was detected in 9 samples with MY09/11-RFLP,
and restriction after P1/P2 amplification gave 2 patterns.
The HPV6a pattern was found in 4 samples, and HPV6b
was found in 5 samples. The HinfI and KpnI enzymes di-
gested amplification product and this led to the determi-
nation of HPV6a, while HPV6b had no digestion. There
were no differences in restriction patterns for the other
10 enzymes (Table 3, Figure 1, 2).
Discussion
The PCR-RFLP strategy enables the detection and
typing of all known and yet unknown genital HPVs.
However, detection of new HPV genotypes, variants and
subtypes remains difficult when using type-specific prim-
ers or probes. Generic primers for conserved regions,
such as the L1 (MY09/11) are very useful for the detec-
tion of these viruses10. The rates of detection of HPV
DNA with only one generic primer pair are not satisfac-
tory10,13. This study validated the combination of two sets
of consensus primers (MY09/MY11 and P1/P2). MY09/
MY11 is one of the most commonly used sets of degener-
ate primers, which amplifies the conserved region L1
mentioned above9,14. The other set of consensus primers
was P1/P2. With the last one primer set it is possible to
promote the amplification of a 526–594 bp fragment of
E1 ORF, which contains sequences from different muco-
sotropic HPV types12. To the best of our best knowledge,
no other author has used this combinations of primers.
This combination provided a higher sensitivity in
HPV detection than the use of one primer pair alone.
This difference was not statistically significant (c-square
test p=0.1824), in contrast to the similar research made
by Kado and coworkers10. In their study they used as
many as five different sets of PCR primers and achieved
a significantly higher rate of HPV detection. Namely,
only 34 of 77 (44%) HPV DNAs were amplified by all of
the primer pairs used. The combined overall detection
rate was even 76/77 (99%). The combination of five meth-
ods is labor intensive and too expensive for routine work.
It was also expected that combining the previously de-
scribed methods would result in finding more different
HPV types than with one method, lead to resolving some
mixed infections and probably to finding subtypes (vari-
ants) of some HPV types.
Although 12 different restriction enzymes were used
in this research, the RFLP method performed on E1 ORF
was weakly discriminatory in comparison with the most
commonly used RFLP method (MY09/ MY011). The in-
tention of this study was to screen the enzymes on the
part of the gene E1 and choose those that digest the re-
gion of interest. This method resulted finding in 7 differ-
ent types (out of 17 that were typed with MY09/11-RFLP).
A recently published study described a PCR-RFLP-based
method which permits discrimination of all known mu-
cosal HPV types (49 HPV types and 2 subtypes)15. This
range of HPV identification greatly exceeds the number
of types characterized by any currently available com-
mercial assays or by any other genotyping methodology
based on RFLP analysis9,16–18.
In epidemiological studies, sequence variations can be
used as a marker to track the spread of the virus in con-
tact networks through populations19,20. HPV 16 is known
to have a number of variants, each with a different geo-
graphic distribution. Some are more often associated
with invasive neoplasias. HPV variant classes and sub-
classes of the HPV 16 were identified by sequencing re-
gions of the E6, L1 and E2 genes21–26.Variants of some
other high-risk types were also found (HPV 18, HPV 31,
HPV 35, HPV 68)21,23.
HPV infections are extremely common and the pres-
ence of the same high-risk type in cervical specimens
could be due to reinfection. Subtyping (the determina-
tion of the HPV variants) could help in a more precise in-
vestigation of persistence, as the most important predic-
tor for the development of cervical carcinoma.
Two variants of HPV 16 and HPV 6 were found by
combining two RFLP methods. The restriction method
was carried out with 12 enzymes after P1/P2 amplifica-
tion, but the following enzymes were sufficient for proof
of the HPV 16 subtypes: AluI, HaeIII, EcoRI and Dde.
The HPV 6 subtypes were determined with enzymes
HinfI and KpnI. For the other 10 enzymes there were no
differences in digestion.
Future studies are also required to provide compre-
hensive information about the significance and poten-
tional role of these E1 variations of HPV 16 among dif-
ferent groups of women (normal, CIN I, CIN II/III). In
this study HPV 16b was found in 17 samples obtained
from women with CIN2 and 3, while HPV 16a was found
with 7 women with CIN2 and 3. This research was per-
formed on a relatively small number of samples and fur-
ther research on a larger number of samples is necessary.
In conclusion, a higher degree of HPV detection is
achieved by combining these two PCR-RFLP methods
than by using one pair of primers alone. This method is
much easier to perform than sequencing, so it could be
used as an alternative method for HPV subtyping and
also for epidemiological research. We did not find any lit-
erature describing HPV 16 and HPV 6 subtype detection
using the RFLP method. The importance of HPV 16 sub-
types is more obvious, for example, in the detection of
persistence, while the importance of HPV 6 subtypes is
less well known. Grassman and his collaborators did not
find a link between HPV 6 variants and different onco-
gene activity of the promoter27,28.
Because these viruses have extraordinary genetic va-
riability, it is important to have simple and easy methods
for detecting subtypes than can be uncovered by current
vaccine. The possibility of infection with several molecu-
lar variants of specific HPV type at the same time should
also be studied, and whether natural genetic variability
occurs during persistent infection. Therefore, further re-
search should focus on the currently available molecular
methods for HPV typing and the evaluation of RFLP re-
striction efficacy in different HPV regions.
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DETEKCIJA MOLEKULARNIH VARIJANTI HUMANIH PAPILOMA VIRUSA TIPOVA 16 I 6
U @ENA S RAZLI^ITIM CITOLO[KIM PROMJENAMA RFLP ANALIZOM
S A @ E T A K
Infekcije uzrokovane humanim papiloma virusima (HPV) su ~este te prisutnost istog genotipa visokog rizika u cer-
vikalnim uzorcima mo`e zna~iti reinfekciju ili perzistenciju. Perzistentna infekcija je najva`niji prediktor za razvoj
karcinoma vrata maternice. Cilj ovog istra`ivanja je validacija dva seta primera: MY09/11 koij amplificiraju dio gena L1
i P1/P2 koji amplificiraju dio gena E1. Produkt amplifikacije s primerima MY09/11 izlo`en je digestiji sa 6 restrikcijskih
enzima (RE), a produkt amplifikacije s P1/P2 s 12 RE. Analizirani su uzorci od 110 `ena koje su se lije~ile u Klinici za
`enske bolesti i porode KBC Zagreb. Amplifikacijom s P1/P2 dobiveno je 98 (89,1%) pozitivnih uzoraka, a s MY09/11 94
(85,5%). Sa MY09/11-RFLP tehnikom dobiveno je 17 razli~itih genotipova, a sa P1/P2-RFLP tehnikom 7. S oba para
primera bilo je pozitivno 82 uzorka; 16 uzoraka bilo je pozitivno samo s P1/P2, a 12 samo s MY09/11. HPV 16 je na|en u
39 uzoraka tehnikom MY09/11-RFLP; od toga su P1/P2-RFLP tehnikom na|ene 2 varijante (2 razli~ita obrasca raz-
gradnje) koriste}i 3 RE (Dde I, Hae III and Eco I). HPV 6 je na|en u 9 uzoraka tehnikom MY09/11-RFLP; od toga su
P1/P2-RFLP tehnikom na|ene 2 varijante koriste}i samo jedan RE (Hinf I). Kombinacijom 2 PCR-RFLP tehnike otkri-
veni su subtipovi HPV 16 i HPV 6.
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